Establish FeNO cut-off value for predicting Budesonide-formoterol response in chronic cough suggestive of CVA patients.

Trial Identifier:	D589BL00076
Sponsor:	AstraZeneca
Start Date:	October 2024
Primary Completion Date:	July 2025
Study Completion Date:	July 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	Beijing, CN, 100034
CN	Beijing, CN, 100029
CN	Benxi, CN, 117000
CN	Chengdu, CN, 610014
CN	Chengdu, CN, 610041
CN	Chongqing, CN, 400000
CN	dongguan, CN, CN-523326
CN	Fenyang, CN, 032299
CN	fuzhou, CN, 350005
CN	Guangzhou, CN, 510163
CN	Guangzhou, CN, 510515
CN	Guangzhou, CN, 510000
CN	Guiyang, CN, 550002
CN	Heifei, CN, 230011
CN	Heze, CN, 274400
CN	Huizhou, CN, 516002
CN	Jiaxing, CN, 314001
CN	Jinhua, CN, 321000
CN	Liuzhou, CN, 545006
CN	Nanchang, CN, 330006
CN	Nanjing, CN, 211100
CN	Nanyang, CN, 473000
CN	quanzhou, CN, 362000
CN	Shanghai, CN, 201114
CN	Shanghai, CN, 310000
CN	Shangqiu, CN, 476100
CN	Shenzhen, CN, 518020
CN	Shijiazhuang, CN, 050001
CN	Suzhou, CN, 657299
CN	Taiyuan, CN, 030001
CN	Taiyuan, CN, 030032
CN	Weifang, CN, 261000
CN	wenzhou, CN, 325027
CN	Wenzhou, CN, 325000
CN	Xi'an, CN, 710006
CN	Xiangtan, CN, 411228
CN	Yantai City, CN, 264000
CN	Zhengzhou City, CN, 450000
CN	Zunyi, CN, 563100

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company